Arsenic Trioxide and the Phosphoinositide 3-Kinase/Akt Pathway in Chronic Lymphocytic Leukemia

[Guest guest]

BlankArsenic Trioxide and the Phosphoinositide 3-Kinase/Akt Pathway in Chronic

Lymphocytic Leukemia

1.. Dennis J. Goussetis1,2 and

2.. Leonidas C. Platanias1,2

+ Author Affiliations

1.. Authors' Affiliations:1 H. Lurie Comprehensive Cancer Center and

Division of Hematology/Oncology, Northwestern University Medical School and

2 Brown, Virginia Medical Center, Chicago, Illinois

1.. Corresponding Author:

Leonidas C. Platanias, H. Lurie Comprehensive Cancer Center, 303 East

Superior Street, Lurie 3-107, Chicago, IL 60611. Phone: 312-503-4267; Fax:

312-908-1372; E-mail: l-platanias@....

Abstract

Simultaneous targeting of the phosphoinositide 3-kinase (PI3K)/Akt pathway

increases arsenic trioxide (ATO)–dependent cytotoxicity of chronic lymphocytic

leukemia (CLL) cells, whereas it has no significant effects on normal

lymphocytes. Combinations of ATO with small molecules that target PI3K and/or

Akt may provide a novel approach for the treatment of CLL. Clin Cancer Res;

16(17); 4311–2. ©2010 AACR.